A drug solution administration device that detects an administration condition of a drug solution with higher accuracy. The drug solution administration device includes a pusher, a drive mechanism configured to move the pusher forward and backward with respect to a distal end opening of the drug solution container, and a control unit configured to control operation of the drive mechanism. The drive mechanism includes a motor configured to generate driving force for moving the pusher forward and backward, and a rotation detection unit configured to detect rotation of the motor. The control unit has an operation confirmation function of confirming an operating condition of the motor on the basis of a detection result of the rotation detection unit. After confirming that the motor is stopped by the operation confirmation function, the control unit starts reverse rotation of the motor to determine whether or not the pusher moves backward.

Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.

Certain aspects of the present disclosure provide methods and apparatus for measuring an injection catheter needle insertion depth and/or injection solution efficacy. An example injection catheter may include a catheter tube and a retractable, electrically conductive needle disposed in the catheter tube and configured to extend from the catheter tube. The injection catheter may also include one or more electrodes disposed at a distal portion of the catheter tube, an electrical lead coupled to the needle, and electrical leads coupled to the electrode(s). An example method includes deploying such an injection catheter adjacent to the tissue, extending a needle into the tissue, receiving electrical signals from an electrical lead coupled to the needle and from other electrical leads coupled to the electrode(s), determining a bioelectrical parameter based on the received electrical signals, and determining a depth of the needle inserted into the tissue based on the bioelectrical parameter.

The invention relates to a mobile selection system for selecting medical accessories comprising a control system, a user interface and a treatment cart. The treatment cart comprises a plurality of storage devices each having at least two storage areas for a respective accessory type. The control system thereby implements a selection method having the following method steps. The treatment identifier of the treatment to be performed is determined in one method step via the user interface. In a further method step, a plurality of accessory set parameters which characterize a medical accessory set are determined on the basis of an accessory database and on the basis of the treatment identifier of the treatment to be performed. The treatment cart comprises a release mechanism, wherein the control system is designed to control the release mechanism so as to release those medical accessories for which at least one of the storage devices comprises storage area for their accessory types and which are characterized by the accessory set parameters on which the control is based.

The described technology generally includes systems and processes for a PD optimization process may operate to estimate, predict, or otherwise determine the value of PD dose variables values based on patient characteristics and/or PD prescription information. In one embodiment, a PD optimization process may be or may include a UFV determination process, operative to determine a predicted UFV for a patient. In some embodiments, the UFV determination process may include training a computational model to generate a predicted UFV output based on input of patient characteristics, PD prescription information, PD outcomes (for instance, UFV), and/or historical information associated with patient characteristics, PD prescription information, and/or PD outcomes. In some embodiments, a feedback control process with continuous Intraperitoneal Pressure (IPP) and hydration status measurements may be used to keep the hydration status of the patient within a target level ran. Other embodiments are described.

In one embodiment, an infusion set and sensor assembly delivered within a subject is disclosed. The assembly includes a cannula that is terminated at a cannula opening. The assembly further includes a sharp that is at least partially within the hollow of the cannula. A sensor having a proximal end and a distal end is also included in the assembly. The proximal end of the sensor is held in a fixed location while the distal end is retained with a portion of the cannula. The sensor further includes sensor slack, wherein transitioning the sharp from a first position to a second position simultaneously inserts the cannula and sensor to a desired insertion depth within a subject via a single point of insertion.

A blood pump is described that includes an impeller having proximal and distal bushings, at least one helical elongate element, a spring that is disposed inside of the helical elongate element and along an axis around which the helical elongate element winds, and a film of material supported between the helical elongate element and the spring. A frame is disposed around the impeller. A flexible elongate element extends radially from the spring to the helical elongate element, and maintains the helical elongate element within a given distance from the spring, to thereby maintain a gap between an outer edge of a blade of the impeller and an inner surface of the frame, during rotation of the impeller. Other applications are also described.

Methods and systems are provided for delivering anesthetic agent to a patient. In one embodiment, an anesthetic vaporizer includes a sump configured to hold a liquid anesthetic agent; an ultrasonic transducer coupled to a bottom of the sump and at least partially disposed within the sump; a vaporizing chamber fluidically coupled to the sump; and a heating element coupled to the vaporizing chamber and configured to increase a temperature of a surface disposed within the vaporizing chamber.

A motion sickness control system for a vehicle includes a vibrator. The motion sickness control system includes a sensor configured to measure vibration of the vehicle. The motion sickness control system includes a computer having a processor and a memory storing instructions executable by the processor to actuate the vibrator at a target frequency based on the measured vibration of the vehicle. The target frequency attenuates the measured vibration of the vehicle.

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.